Melissa Traub
Family · Rapid City, SDNPI 1972961324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 34.2% of the total. 2025 is the largest year on record at $871, 2.1 times the $416 reported in 2021. Among family clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$994
- Amgen$450
- Medtronic$341
- Dexcom, Inc.$274
- Bayer$161
- Tandem Diabetes Care, Inc.$160
- plus $521 from 10 others
What the payments were for
- Food & beverage$2,80597%
- Education$973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $994 |
| Amgen(2 entities) | 20 | $450 |
| Medtronic | 7 | $341 |
| Dexcom, Inc. | 12 | $274 |
| Bayer | 3 | $161 |
| Tandem Diabetes Care, Inc. | 2 | $160 |
| Abbott | 3 | $107 |
| Novartis | 5 | $83 |
| Merck | 1 | $63 |
| Lilly USA, LLC | 4 | $61 |
| Pfizer | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Ascendis Pharma Endocrinology Inc | 2 | $43 |
| Boehringer Ingelheim | 2 | $30 |
| Johnson & Johnson | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$242
- Kerendia$125
- Ozempic$117
- MINIMED 780G$113
How this compares
$2,902 in reported general payments places this provider in the 90th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 156 | $215,140 |
| JardianceEmpagliflozin | 121 | $132,267 |
| MounjaroTirzepatide | 76 | $89,682 |
| Tresiba Flextouch U-200Insulin Degludec | 61 | $82,522 |
| FarxigaDapagliflozin Propanediol | 62 | $59,201 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 41 | $41,325 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $40,637 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $34,116 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 33 | $31,093 |
| TrulicityDulaglutide | 24 | $29,213 |
| Novolog FlexpenInsulin Aspart | 48 | $23,687 |
| Teriparatide | 11 | $22,905 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $17,993 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $16,335 |
| JanuviaSitagliptin Phosphate | 14 | $14,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $994 | $260,365208 claims |
| Boehringer IngelheimJardiance | $30 | $132,267121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $61 | $118,896100 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $49 | $17,99312 claims |
| MerckJanuvia | $63 | $14,97314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family providers in South Dakota.
Other family in Rapid City
- Claudia HouglandRapid City$9K
- Melissa OwensRapid City$6K
- Kristen DirksRapid City$5K
- Janessa HuntRapid City$5K
- Rebecca ChristensenRapid City$5K
- Jamie SlettedahlRapid City$4K
- Kristy SchumacherRapid City$4K
- Vanessa PribilRapid City$3K
- Rachel WaddellRapid City$3K
- Kelsey JohnsonRapid City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.